Definium Posts $1.05B Cash Pile, Adds Positive DT402 Autism Data in Q3 Update
DFTX has more than doubled off its 52-week low of $10.465.
Summary
Definium closed Q3 2026 with roughly $1.05 billion in cash, cash equivalents and investments, up from $411.6 million at year-end 2025, and says that funds operations into 2030. The quarter's net loss narrowed to $51.0 million, or 46 cents a share, from $67.3 million a year earlier, helped by a $12.35 million gain on the fair value of its 2022 USD financing warrants and higher interest income, even as R&D rose to $46.1 million and G&A to $26.1 million. The release also adds new clinical data: positive initial Phase 2a results for DT402 in five adults with ASD, with improvements across socialization and communication measures, though the study was open-label and not powered for statistical conclusions. This follows the Voyage and Panorama Phase 3 wins and the MDD Breakthrough Therapy designation already reported, and management now points to an NDA filing for DT120 ODT in the first half of 2027. The balance sheet removes near-term financing risk; the open question is execution on the Ascend study and the regulatory path, with Ascend topline data expected in 2027.
At the time of this announcement, DFTX was trading at $35.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $10.46 to $49.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.